Sara Holstein, MD
Hematology · Omaha, NENPI 1235349275
Payments from drug & device makers
Across 172 payments — averaging $16,120 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1.6M
- Bristol Myers Squibb$612K
- Janssen Research & Development, LLC$302K
- Celularity Inc.$141K
- AbbVie$60K
- Karyopharm Therapeutics Inc.$33K
- plus $71K from 9 others
Across 1 payment — averaging $68,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$69K
What the payments were for
- Consulting fees$62,12895%
- Speaking & faculty fees$1,5752%
- Travel & lodging$1,1042%
- Food & beverage$4081%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,553,779 |
| Bristol Myers Squibb | 9 | $612,065 |
| Janssen Research & Development, LLC | 47 | $301,794 |
| Celularity Inc. | 5 | $141,272 |
| AbbVie | 12 | $59,926 |
| Karyopharm Therapeutics Inc. | 1 | $32,512 |
| Pfizer | 7 | $30,560 |
| GSK | 8 | $12,030 |
| E.r. Squibb & Sons, L.L.C. | 4 | $9,550 |
| Sanofi | 1 | $5,752 |
| Janssen Scientific Affairs, LLC | 3 | $5,138 |
| Genentech, Inc. | 5 | $5,055 |
| Johnson & Johnson | 2 | $2,982 |
| Secura Bio, Inc. | 1 | $200 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 398 | $6,747,665 |
| PomalystPomalidomide | 54 | $1,077,509 |
| Lenalidomide | 22 | $313,261 |
| EliquisApixaban | 36 | $25,364 |
| XareltoRivaroxaban | 11 | $14,235 |
| SavaysaEdoxaban Tosylate | 13 | $4,996 |
| BexseroMeningococcal B Vaccine,4-Comp | 18 | $4,004 |
| TwinrixHepatitis A And B Vaccine/Pf | 29 | $3,437 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 15 | $2,875 |
| Acyclovir | 312 | $2,826 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 17 | $2,530 |
| ValacyclovirValacyclovir Hcl | 13 | $1,744 |
| Colestipol Hcl | 11 | $1,384 |
| IpolPoliomyelitis Vaccine, Killed | 31 | $1,264 |
| Potassium Chloride | 28 | $1,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $612,065 | $6,747,665398 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $9,550 | $1,077,50954 claims |
| PfizerEliquis | $30,560 | $25,36436 claims |
| Johnson & JohnsonXarelto | $2,982 | $14,23511 claims |
| GSKBexsero, Twinrix, Shingrix | $12,030 | $10,31662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other hematology in Omaha
- Christopher DangeloOmaha$3.2M
- Zaid Al-KadhimiOmaha$722K
- Alex NesterOmaha$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.